Cellectar Biosciences, Inc.
CLRB
$4.88
-$0.05-1.01%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.97M | 6.54M | 7.83M | 6.36M | 4.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.40M | 12.74M | 13.33M | 13.70M | 12.00M |
| Operating Income | -6.40M | -12.74M | -13.33M | -13.70M | -12.00M |
| Income Before Tax | -6.60M | -2.29M | -14.66M | -919.40K | -26.64M |
| Income Tax Expenses | -- | 66.00K | -- | -- | -- |
| Earnings from Continuing Operations | -6.60M | -2.36M | -14.66M | -919.40K | -26.64M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.60M | -2.36M | -14.66M | -919.40K | -26.64M |
| EBIT | -6.40M | -12.74M | -13.33M | -13.70M | -12.00M |
| EBITDA | -6.34M | -12.68M | -13.26M | -13.64M | -11.91M |
| EPS Basic | -4.30 | -1.68 | -11.18 | -0.77 | -27.24 |
| Normalized Basic EPS | -2.69 | -1.02 | -6.99 | -0.48 | -17.02 |
| EPS Diluted | -4.30 | -1.68 | -12.13 | -5.43 | -27.24 |
| Normalized Diluted EPS | -2.69 | -1.02 | -6.91 | -0.46 | -17.02 |
| Average Basic Shares Outstanding | 1.54M | 1.40M | 1.31M | 1.19M | 978.20K |
| Average Diluted Shares Outstanding | 1.54M | 1.40M | 1.33M | 1.25M | 978.20K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |